Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma

Article Oncology

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

Arlene O. Siefker-Radtke et al.

Summary: This study evaluated the long-term efficacy and safety of Erdafitinib in patients with locally advanced or metastatic urothelial carcinoma. The results showed consistent activity and manageable safety profile in these patients.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy

Ryul Kim et al.

Summary: This study explores the genomic and transcriptomic characteristics of bladder cancer (BC) and investigates the impact of immune checkpoint inhibitors (ICI) on its treatment. The results show that a subset of patients express PD-L1 and have a higher tumor mutational burden. Furthermore, immune-responsive pathways and the CTLA4 pathway are enriched in PD-L1 positive BC. The study provides a theoretical basis for the application of dual checkpoint inhibition in bladder cancer treatment.

CANCER RESEARCH AND TREATMENT (2022)

添加到收藏夹

Article Oncology

Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma

Tetsuya Yumioka et al.

Summary: Platinum-based chemotherapy rechallenge after pembrolizumab showed maintained activity with a median overall survival of 11.2 months, an 85.7% disease control rate, and neutropenia of grade >= 3 occurring in most patients.

ANTICANCER RESEARCH (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial

Thomas Powles et al.

Summary: In a recent study of advanced urothelial cancer patients, avelumab in combination with best supportive care significantly prolonged overall survival compared to care alone, with factors such as PD-L1 expression, tumor mutational burden, immune activity genes, and Fcγ receptor variants being positively associated with survival benefit. Individual biomarkers alone were not sufficient to predict therapy response, but multi-parameter models integrating genomic alterations, immune responses, and tumor growth showed potential for predictive utility. These findings highlight the complexity of biological pathways in immune checkpoint inhibition therapy and suggest the need for multiple biomarkers to identify patients who would benefit from treatment.

NATURE MEDICINE (2021)

添加到收藏夹

Article Oncology

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial

Evan Y. Yu et al.

Summary: Enfortumab vedotin showed promising efficacy in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma previously treated with PD-1 or PD-L1 inhibitors, providing a new treatment option for a patient population with a high unmet need.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer

Thomas Powles et al.

Summary: Durvalumab combined with different targeted therapies in advanced urothelial cancer did not meet expected efficacy levels in this study. Biomarker analysis showed the correlation between FGFRm and ctDNA with clinical outcomes. There are remaining doubts about the targeted/immune therapy approach in AUC.

NATURE MEDICINE (2021)

添加到收藏夹

Article Oncology

Real-world outcomes in locally advanced or metastatic urothelial carcinoma following platinum and PD-1/L1 inhibitor therapy

Zsolt Hepp et al.

Summary: This study investigated real-world overall survival (rwOS) and progression-free survival (rwPFS) in patients with locally advanced/metastatic urothelial carcinoma postplatinum and post-programmed death receptor-1/death ligand 1 inhibitors. The results showed that the median rwOS ranged from 7.6 to 8.9 months, and rwPFS ranged from 2.9 to 3.6 months, indicating a need for more effective and safer treatments in this patient population.

FUTURE ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease

Risa L. Wong et al.

Summary: Patients with metastatic urothelial carcinoma who received subsequent platinum-based chemotherapy had better overall survival and disease control rates compared to those who received non-platinum-based chemotherapy after first-line treatment. This suggests that platinum rechallenge may be a more effective option for these patients.

ONCOLOGIST (2021)

添加到收藏夹

Article Oncology